ES2950569T3 - (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk - Google Patents

(S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk Download PDF

Info

Publication number
ES2950569T3
ES2950569T3 ES18203086T ES18203086T ES2950569T3 ES 2950569 T3 ES2950569 T3 ES 2950569T3 ES 18203086 T ES18203086 T ES 18203086T ES 18203086 T ES18203086 T ES 18203086T ES 2950569 T3 ES2950569 T3 ES 2950569T3
Authority
ES
Spain
Prior art keywords
compound
disease
benzamide
btk
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18203086T
Other languages
English (en)
Spanish (es)
Inventor
Tjeerd A Barf
Christiaan Geradus Johannes Maria Jans
Man Adrianus Petrus Antonius De
Arthur A Oubrie
Hans C A Raaijmakers
Johannes Bernardus Maria Rewinkel
Jan-Gerard Sterrenburg
Jacobus C H M Wijkmans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47557677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2950569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme BV filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2950569T3 publication Critical patent/ES2950569T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES18203086T 2011-07-19 2012-07-11 (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk Active ES2950569T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509397P 2011-07-19 2011-07-19
EP11174578 2011-07-19

Publications (1)

Publication Number Publication Date
ES2950569T3 true ES2950569T3 (es) 2023-10-11

Family

ID=47557677

Family Applications (3)

Application Number Title Priority Date Filing Date
ES19215783T Active ES2904707T3 (es) 2011-07-19 2012-07-11 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de Btk
ES12733505T Active ES2708224T3 (es) 2011-07-19 2012-07-11 4-Imidazopiridazín-1-il-benzamidas y 4-imidazotriazín-1-il-benzamidas como inhibidores de Btk
ES18203086T Active ES2950569T3 (es) 2011-07-19 2012-07-11 (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES19215783T Active ES2904707T3 (es) 2011-07-19 2012-07-11 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de Btk
ES12733505T Active ES2708224T3 (es) 2011-07-19 2012-07-11 4-Imidazopiridazín-1-il-benzamidas y 4-imidazotriazín-1-il-benzamidas como inhibidores de Btk

Country Status (38)

Country Link
US (7) US9290504B2 (enExample)
EP (4) EP2734522B1 (enExample)
JP (6) JP5826931B2 (enExample)
KR (2) KR101802689B1 (enExample)
CN (2) CN103889987B (enExample)
AU (4) AU2012285987C1 (enExample)
BR (1) BR112014001255B1 (enExample)
CA (1) CA2841886C (enExample)
CL (1) CL2014000130A1 (enExample)
CO (1) CO6940411A2 (enExample)
CR (1) CR20140030A (enExample)
CY (2) CY2021010I2 (enExample)
DK (2) DK3689878T3 (enExample)
DO (1) DOP2014000008A (enExample)
EA (2) EA037644B1 (enExample)
EC (1) ECSP14013217A (enExample)
ES (3) ES2904707T3 (enExample)
GT (1) GT201400009A (enExample)
HR (2) HRP20212021T1 (enExample)
HU (3) HUE041987T2 (enExample)
IL (3) IL230511B (enExample)
IN (1) IN2014CN00408A (enExample)
LT (1) LT2734522T (enExample)
MA (1) MA35348B1 (enExample)
MX (1) MX342983B (enExample)
MY (1) MY192354A (enExample)
PE (1) PE20141681A1 (enExample)
PH (2) PH12014500148A1 (enExample)
PL (2) PL3689878T3 (enExample)
PT (1) PT3689878T (enExample)
RS (2) RS62760B1 (enExample)
SG (1) SG10201605913VA (enExample)
SI (2) SI3689878T1 (enExample)
SM (2) SMT202100729T1 (enExample)
TN (1) TN2014000027A1 (enExample)
UA (1) UA115312C2 (enExample)
WO (1) WO2013010868A1 (enExample)
ZA (1) ZA202109164B (enExample)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809273B2 (en) * 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
CN103534258B (zh) 2011-05-17 2016-09-14 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
SI3689878T1 (sl) 2011-07-19 2021-12-31 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-il-benzamidi in 4-imidazotriazin-1-il-benzamidi kot Btk-zaviralci
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
LT3181567T (lt) 2012-09-10 2019-07-25 Principia Biopharma Inc. Pirazolpirimidino junginiai kaip kinazės slopikliai
KR20150061651A (ko) * 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
JP6313772B2 (ja) * 2012-10-04 2018-04-18 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤である置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
HRP20181367T4 (hr) 2012-11-01 2021-11-26 Infinity Pharmaceuticals, Inc. Liječenje raka korištenjem modulatora izoforme pi3 kinaze
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
EP2948458B1 (en) 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3003309B1 (en) * 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9738648B2 (en) * 2013-07-31 2017-08-22 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
KR20160093062A (ko) 2013-12-05 2016-08-05 아세르타 파마. 비.브이. Pi3k 억제제 및 btk 억제제의 치료적 조합
WO2015095099A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
WO2016019233A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
PT3179991T (pt) 2014-08-11 2021-11-26 Acerta Pharma Bv Combinações terapêuticas de um inibidor de btk e um inibidor de bcl-2
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
TW201609099A (zh) * 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
RU2658821C1 (ru) 2014-08-18 2018-06-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Соль моноциклического производного пиридина и ее кристалл
EP3191098A4 (en) * 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016055982A1 (en) * 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
ES2843323T3 (es) * 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106626A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106629A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106623A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106627A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016128912A1 (en) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
CA2974937C (en) 2015-03-25 2023-09-05 National Cancer Center Therapeutic agent for bile duct cancer
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
SI3317281T1 (sl) 2015-07-02 2020-08-31 Acerta Pharma B.V. Trdne oblike in formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin -2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US10736893B2 (en) * 2015-11-06 2020-08-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
CN115177619A (zh) 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
US20190008869A1 (en) 2016-01-13 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of an Antifolate and a BTK Inhibitor
CN109600989B (zh) 2016-06-29 2022-11-04 普林斯匹亚生物制药公司 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的改性的释放制剂
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
JP6715357B2 (ja) * 2016-06-30 2020-07-01 杭州三因泰医薬科技有限公司Ｈａｎｇｚｈｏｕ Ｓａｎｙｉｎｔａｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． イミダゾピリジンアミンフェニル誘導体およびその使用
CN109851620B (zh) * 2016-08-17 2020-08-07 深圳市塔吉瑞生物医药有限公司 用于抑制酪氨酸激酶活性的稠合双环类化合物
US10899767B2 (en) 2016-10-05 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
ES2856248T3 (es) * 2016-12-21 2021-09-27 Acerta Pharma Bv Inhibidores de imidazopirazina de la tirosina quinasa de Bruton
WO2018115965A1 (en) 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN106588937B (zh) * 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
WO2018134786A1 (en) 2017-01-19 2018-07-26 Acerta Pharma B.V. Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase
CN106831787B (zh) 2017-01-20 2018-10-23 成都倍特药业有限公司 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
WO2018148961A1 (zh) * 2017-02-20 2018-08-23 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途
US10314844B2 (en) 2017-02-24 2019-06-11 Gilead Sciences, Inc. Inhibitors of Bruton's tyrosine kinase
JP7014811B2 (ja) 2017-02-24 2022-02-01 ギリアド サイエンシズ， インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
MX2019011116A (es) * 2017-03-22 2020-02-05 Liao Xibin Inhibidores de la tirosina quinasa de bruton.
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
CA3058682A1 (en) 2017-04-20 2018-10-25 Apotex Inc. Processes for the preparation of acalabrutinib and intermediates thereof
US10717740B2 (en) 2017-06-13 2020-07-21 Dr. Reddy's Laboratories Limited. Solid forms of acalabrutinib and process for preparation thereof
CN107522701B (zh) * 2017-09-01 2019-11-08 苏州富士莱医药股份有限公司 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法
CN107602564B (zh) * 2017-09-20 2019-08-30 南京亘泰医药技术有限公司 布鲁顿酪氨酸激酶抑制剂
US20200289506A1 (en) 2017-09-25 2020-09-17 Astrazeneca Ab Combination of a btk inhibitor and an inhibitor or cdk9 to treat cancer
CN109836416B (zh) * 2017-11-27 2023-02-03 苏州鹏旭医药科技有限公司 一种化合物的制备方法
EP3706740A4 (en) * 2017-11-06 2021-07-28 Suzhou Pengxu Pharmatech Co., Ltd. METHOD FOR MANUFACTURING ACALABRUTINIB
EP3736273A4 (en) * 2018-01-05 2021-02-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. NEW ACALABRUTINIB CRYSTAL FORM AND THE MANUFACTURING METHOD AND USE OF IT
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
CN110256438B (zh) * 2018-03-12 2020-07-17 新发药业有限公司 一种阿可替尼的制备方法
KR20200135945A (ko) 2018-03-28 2020-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종 치료제
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
TW202014184A (zh) 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
WO2019239374A1 (en) 2018-06-13 2019-12-19 Acerta Pharma B.V. Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
KR20210022650A (ko) 2018-06-19 2021-03-03 리제너론 파아마슈티컬스, 인크. 항-인자 XII/XIIa 항체 및 이의 용도
EP3587421A1 (en) 2018-06-29 2020-01-01 Sandoz AG Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
MA53485A (fr) * 2018-08-29 2021-12-08 Acerta Pharma Bv Procédés de préparation de 4-(8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl] imidazo[1,5-a]-pyrazin-1-yl)n-(pyridin-2-yl)-benzamide
WO2020053795A2 (en) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Process for the preparation of acalabrutinib and its intermediates
US12384784B2 (en) 2018-09-25 2025-08-12 Cipla Limited Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor
CN109020977B (zh) * 2018-10-26 2020-11-13 安庆奇创药业有限公司 一种Acalabrutinib的制备方法
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN111377929A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种可用于治疗白血病阿卡替尼(Acalabrutinib)制备的方法
CN111377928A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种制备Acalabrutinib的方法
US12435079B2 (en) 2019-01-18 2025-10-07 Xibin Liao Bruton's tyrosine kinase inhibitors
WO2020176761A1 (en) * 2019-02-27 2020-09-03 Optikira, LLC Imidazolopyrazine compounds for ire1 inhibition
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020198429A1 (en) * 2019-03-27 2020-10-01 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
CN110563733A (zh) * 2019-09-12 2019-12-13 安帝康（无锡）生物科技有限公司 作为选择性btk抑制剂的咪唑并吡嗪类化合物
KR20220080179A (ko) 2019-10-14 2022-06-14 프린시피아 바이오파마, 인코퍼레이티드 (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 면역 혈소판 감소증을 치료하는 방법
DK4054582T3 (da) 2019-11-04 2025-12-01 Astrazeneca Ab Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20220130184A (ko) 2020-01-22 2022-09-26 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태
TWI889851B (zh) 2020-06-19 2025-07-11 荷蘭商艾森塔製藥公司 阿卡拉布替尼馬來酸鹽劑型
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
CN113264938B (zh) * 2021-07-21 2021-11-02 北京鑫开元医药科技有限公司 一种咪唑并[1,5-a]吡嗪-8-胺类化合物、制备方法、药物组合物和应用
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2025125383A1 (en) 2023-12-11 2025-06-19 Synthon B.V. Crystalline forms of acalabrutinib hydrogen maleate
WO2025244678A1 (en) 2024-05-21 2025-11-27 Telios Pharma Inc. Methods of treating indolent systemic mastocytosis

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0200403A3 (en) 1998-09-18 2004-07-28 Abbott Gmbh & Co Kg Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
SG132683A1 (en) 2003-10-15 2007-06-28 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
MY143225A (en) 2004-04-02 2011-03-31 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
CN102936250B (zh) 2005-11-17 2014-07-09 Osi医药有限责任公司 稠合双环mTOR抑制剂
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP5372737B2 (ja) 2006-03-13 2013-12-18 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Ｅｇｆｒキナーゼ阻害剤およびｅｇｆｒキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療
ES2616789T3 (es) 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
ES2562215T3 (es) * 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
CN101896177A (zh) 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
WO2009126691A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
JP5656976B2 (ja) * 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
WO2011095556A1 (en) * 2010-02-08 2011-08-11 N.V. Organon 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
KR101537148B1 (ko) 2010-05-31 2015-07-15 오노 야꾸힝 고교 가부시키가이샤 푸리논 유도체
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
BR112013029508B1 (pt) 2011-05-17 2022-05-03 Principia Biopharma, Inc. Composto, composição farmacêutica, e, uso do referido composto
WO2013003629A2 (en) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Methods and compositions for inhibition of bone resorption
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
SI3689878T1 (sl) * 2011-07-19 2021-12-31 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-il-benzamidi in 4-imidazotriazin-1-il-benzamidi kot Btk-zaviralci
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP2734523A1 (en) 2011-07-19 2014-05-28 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
JP6506555B2 (ja) 2011-10-19 2019-04-24 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2948458B1 (en) 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
MX369503B (es) 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)

Also Published As

Publication number Publication date
ES2708224T3 (es) 2019-04-09
IL266894A (en) 2019-07-31
SI3689878T1 (sl) 2021-12-31
JP2016034968A (ja) 2016-03-17
LT2734522T (lt) 2019-02-11
ES2904707T3 (es) 2022-04-05
US20160151364A1 (en) 2016-06-02
HUE056249T2 (hu) 2022-02-28
SG10201605913VA (en) 2016-09-29
ZA202109164B (en) 2025-04-30
MX2014000746A (es) 2014-05-07
AU2016203837A1 (en) 2016-06-30
ECSP14013217A (es) 2015-03-31
RS62760B1 (sr) 2022-01-31
SMT201900029T1 (it) 2019-02-28
RS58177B1 (sr) 2019-03-29
DK3689878T3 (da) 2021-11-08
IL230511B (en) 2019-05-30
HRP20212021T1 (hr) 2022-04-01
MY192354A (en) 2022-08-17
SMT202100729T1 (it) 2022-01-10
AU2012285987C1 (en) 2016-09-08
US20190276456A1 (en) 2019-09-12
EP3689878A1 (en) 2020-08-05
HUS2100012I1 (hu) 2021-05-28
EA034558B1 (ru) 2020-02-20
US20230331729A1 (en) 2023-10-19
KR20160117642A (ko) 2016-10-10
BR112014001255A2 (pt) 2017-02-21
PL3689878T3 (pl) 2022-02-14
JP2020189865A (ja) 2020-11-26
JP6251220B2 (ja) 2017-12-20
JP6617130B2 (ja) 2019-12-11
EA201490300A1 (ru) 2014-05-30
CN106243113A (zh) 2016-12-21
HUE041987T2 (hu) 2019-06-28
PT3689878T (pt) 2022-01-05
US20210230166A1 (en) 2021-07-29
BR112014001255B1 (pt) 2019-07-02
MA35348B1 (fr) 2014-08-01
AU2019275591A1 (en) 2020-01-02
IL291489A (en) 2022-05-01
US10934296B2 (en) 2021-03-02
IL230511A0 (en) 2014-03-31
JP5826931B2 (ja) 2015-12-02
GT201400009A (es) 2017-09-28
AU2012285987B2 (en) 2016-03-10
EA201992270A2 (ru) 2020-01-16
PE20141681A1 (es) 2014-11-14
IN2014CN00408A (enExample) 2015-04-03
DK2734522T3 (en) 2019-02-18
KR101802689B1 (ko) 2017-11-28
KR20140036324A (ko) 2014-03-25
EP2734522B1 (en) 2018-10-31
IL266894B (en) 2022-04-01
US20180179212A1 (en) 2018-06-28
UA115312C2 (uk) 2017-10-25
US20160159810A1 (en) 2016-06-09
CY2021010I1 (el) 2021-06-25
AU2019275591B2 (en) 2020-10-01
EP3495368A1 (en) 2019-06-12
AU2016203837B2 (en) 2018-01-25
CA2841886C (en) 2016-08-16
TN2014000027A1 (en) 2015-07-01
CR20140030A (es) 2014-06-03
US10239883B2 (en) 2019-03-26
EP4249076A2 (en) 2023-09-27
KR101702727B1 (ko) 2017-02-06
JP2022088618A (ja) 2022-06-14
EP3689878B1 (en) 2021-10-06
JP2019108395A (ja) 2019-07-04
EP3495368B1 (en) 2023-05-31
CY1125613T1 (el) 2024-02-16
PH12017500166A1 (en) 2017-09-04
US9758524B2 (en) 2017-09-12
NZ620085A (en) 2016-05-27
PH12017500166B1 (en) 2018-10-26
JP6749444B2 (ja) 2020-09-02
NZ716110A (en) 2017-07-28
DOP2014000008A (es) 2014-04-30
PH12014500148A1 (en) 2014-03-31
CN103889987A (zh) 2014-06-25
JP2018035184A (ja) 2018-03-08
CO6940411A2 (es) 2014-05-09
AU2017279778B2 (en) 2019-09-19
EP2734522A1 (en) 2014-05-28
JP2014520870A (ja) 2014-08-25
PL2734522T3 (pl) 2019-04-30
EA037644B1 (ru) 2021-04-26
HRP20190135T1 (hr) 2019-03-22
CN103889987B (zh) 2016-09-14
MX342983B (es) 2016-10-19
US9290504B2 (en) 2016-03-22
WO2013010868A1 (en) 2013-01-24
AU2017279778A1 (en) 2018-01-25
US9790226B2 (en) 2017-10-17
US20140155385A1 (en) 2014-06-05
AU2012285987A1 (en) 2014-02-06
CA2841886A1 (en) 2013-01-24
CY2021010I2 (el) 2021-06-25
SI2734522T1 (sl) 2019-03-29
CN106243113B (zh) 2018-12-18
EA201992270A3 (ru) 2020-03-31
CL2014000130A1 (es) 2014-08-22
JP7054721B2 (ja) 2022-04-14
EP4249076A3 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
ES2950569T3 (es) (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk
HK40026806B (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
HK40026806A (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
HK40008890A (en) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
HK40096146A (en) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
HK40008890B (en) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
NZ716110B2 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
HK1192752B (en) 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
HK1192752A (en) 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors